Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.29 | $27M | -$22M |
| 2026 Q1 | -0.19 | $27M | -$26M |
| 2025 Q4 | -0.24 | $24M | -$15M |
| 2025 Q3 | 0.18 | $21M | $169M |
| 2025 Q2 | -0.56 | $119,000 | -$20M |
| 2025 Q1 | -0.49 | $219,000 | -$24M |
| 2024 Q4 |
| -0.64 |
| $212,000 |
| -$22M |
| 2024 Q3 | -0.49 | $176,000 | -$17M |